Bris­tol My­ers pays $80M to li­cense an­oth­er Prothena neu­ro­science can­di­date

Bris­tol My­ers Squibb is shelling out $80 mil­lion to Prothena for an ex­clu­sive glob­al li­cense for an ear­ly-stage neu­rode­gen­er­a­tive can­di­date, as the phar­ma gi­ant con­tin­ues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER